Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

1.310 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.160 (3)
Ask (Size) 1.340 (1)
Prev. Close 1.310
Today's Range 1.310 - 1.310
52wk Range 1.050 - 5.860
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's after hours session: top gainers and losers
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
-36.7%
-36.7%
1 Month
-6.4%
-6.4%
3 Month
-31.8%
-31.8%
6 Month
-75.9%
-75.9%
1 Year
-74.3%
-74.3%

More News

Read More
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Host Virtual Investor Event on October 15, 2024
From Climb Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Climb Bio, Inc. - Common Stock publicly traded?
Yes, Climb Bio, Inc. - Common Stock is publicly traded.
What exchange does Climb Bio, Inc. - Common Stock trade on?
Climb Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Climb Bio, Inc. - Common Stock?
The ticker symbol for Climb Bio, Inc. - Common Stock is CLYM on the Nasdaq Stock Market
What is the current price of Climb Bio, Inc. - Common Stock?
The current price of Climb Bio, Inc. - Common Stock is 1.310
When was Climb Bio, Inc. - Common Stock last traded?
The last trade of Climb Bio, Inc. - Common Stock was at 04/14/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.